A case report of secondary B-cell acute lymphoblastic leukemia treated with a combination of FLT3 inhibitor and decitabine

Mengci Hu; Wenzhe Li; Pan Li; Jie Tan; Ya Wang; Ya Wang

doi:10.3389/fonc.2024.1329279

Frontiers in Oncology (Apr 2024)

A case report of secondary B-cell acute lymphoblastic leukemia treated with a combination of FLT3 inhibitor and decitabine

Mengci Hu,
Wenzhe Li,
Pan Li,
Jie Tan,
Ya Wang,
Ya Wang

Affiliations

Mengci Hu: Department of Hematology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China
Wenzhe Li: Department of Endocrinology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China
Pan Li: Department of Hematology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China
Jie Tan: Department of Hematology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China
Ya Wang: Department of Endocrinology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China
Ya Wang: Department of Hubei Provincial Clinical Research Center for Personalized Diagnosis and Treatment of Cancer, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China

DOI: https://doi.org/10.3389/fonc.2024.1329279
Journal volume & issue: Vol. 14

Abstract

Read online

Secondary acute lymphoblastic leukemia (s-ALL) refers to acute lymphoblastic leukemia that occurs after a previous malignant tumor, including therapy-related acute lymphoblastic leukemia (t-ALL) and prior malignant tumor acute lymphoblastic leukemia (pm-ALL). We report a case of a 51-year-old female patient who developed acute lymphoblastic leukemia 14 years after being diagnosed with diffuse large B-cell lymphoma (DLBCL). The patient was unresponsive to conventional chemotherapy for acute lymphoblastic leukemia (ALL) and achieved remission with a combination of sorafenib and decitabine based on the molecular biology characteristics of her B-ALL.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords